YM 16151-1

Known as: YM 16151, YM-16151, YM-16151-1 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2009
0119902009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
BACKGROUND The morbidity and mortality associated with malaria are heightened because of the spread of drug-resistant parasites… (More)
Is this relevant?
2005
2005
18. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1993
1993
The antianginal effects of YM-16151-4, a combined calcium entry blocking and beta 1-adrenoceptor blocking agent, were evaluated… (More)
Is this relevant?
1993
1993
The pharmacological activities of YM-16151-1, a combined calcium entry blocking and beta 1-adrenoceptor blocking agent, and its… (More)
Is this relevant?
1993
1993
The cardiovascular effects of YM-16151-4 were evaluated in rats and dogs. In conscious rats, YM-16151-4 (3-30 mg/kg p.o… (More)
Is this relevant?
1992
1992
Cardiovascular effects of YM-16151-4, a combined calcium entry blocking and beta 1-adrenoceptor blocking agent, were evaluated in… (More)
Is this relevant?
1991
1991
The calcium entry blocking, beta 1-adrenoceptor blocking and hypotensive effects of YM-16151-4 were studied in pithed rats and in… (More)
Is this relevant?
1991
1991
The effects of YM-16151 (1 mg/kg, i.v.), a combined beta 1-adrenoceptor blocking and calcium antagonist drug, on large… (More)
Is this relevant?
1990
1990
The pharmacological properties of YM-16151-1 [(+/-)-dimethyl 4-[2-[4-(2-hydroxy-3-phenoxypropylamino)butoxyl]-5-nitrop hen yl]-2… (More)
Is this relevant?